{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:40:46Z","timestamp":1792766446055,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bcmd.2021.102567","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T22:03:05Z","timestamp":1617314585000},"page":"102567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Co-morbidities and mortality in patients with sickle cell disease in England: A 10-year cohort analysis using hospital episodes statistics (HES) data"],"prefix":"10.1016","volume":"89","author":[{"given":"Fr\u00e9d\u00e9ric B.","family":"Piel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh","family":"Jobanputra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra G.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McGahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2021.102567_bb0005","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10091","key":"10.1016\/j.bcmd.2021.102567_bb0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.bcmd.2021.102567_bb0015","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2010-06-293514","article-title":"Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort","volume":"117","author":"Bernaudin","year":"2011","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.bcmd.2021.102567_bb0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjh.13477","article-title":"How I manage cerebral vasculopathy in children with sickle cell disease","volume":"170","author":"Brousse","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.bcmd.2021.102567_bb0025","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ajh.25202","article-title":"Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: a retrospective-prospective cohort study","volume":"93","author":"Chaturvedi","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102567_bb0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"10037","key":"10.1016\/j.bcmd.2021.102567_bb0035","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","article-title":"Cardiovascular complications and risk of death in sickle-cell disease","volume":"387","author":"Gladwin","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.bcmd.2021.102567_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2018.05.001","article-title":"Biomarker signatures of sickle cell disease severity","volume":"72","author":"Du","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"9","key":"10.1016\/j.bcmd.2021.102567_bb0045","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"9861","key":"10.1016\/j.bcmd.2021.102567_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet."},{"issue":"4 Suppl","key":"10.1016\/j.bcmd.2021.102567_bb0055","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am. J. Prev. Med."},{"issue":"3","key":"10.1016\/j.bcmd.2021.102567_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/pubmed\/fdx172","article-title":"How many people have sickle cell disease in the UK?","volume":"40","author":"Dormandy","year":"2017","journal-title":"J. Public Health"},{"issue":"23","key":"10.1016\/j.bcmd.2021.102567_bb0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.V126.23.71.71","article-title":"Survival in sickle cell disease: data from a well-resourced, national health system setting","volume":"126","author":"Gardner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2021.102567_bb0070","series-title":"A Sickle Crisis? A Report of the National Confidential Enquiry Into Patient Outcome and Death","year":"2008"},{"key":"10.1016\/j.bcmd.2021.102567_bb0075","series-title":"Standards for the Clinical Care of Adults With Sickle Cell Disease in the UK","author":"Sickle Cell Society","year":"2008"},{"key":"10.1016\/j.bcmd.2021.102567_bb0080","author":"National Institute for Health and Care Excellence (NICE) CG143"},{"key":"10.1016\/j.bcmd.2021.102567_bb0085","author":"National Institute for Health and Care Excellence (NICE) QS58"},{"key":"10.1016\/j.bcmd.2021.102567_bb0090","author":"National Institute for Health and Care Excellence (NICE) MTG28"},{"key":"10.1016\/j.bcmd.2021.102567_bb0095","author":"World Health Organisation"},{"key":"10.1016\/j.bcmd.2021.102567_bb0100","author":"NHS Digital"},{"key":"10.1016\/j.bcmd.2021.102567_bb0105","author":"Office of National Statistics (ONS)"},{"key":"10.1016\/j.bcmd.2021.102567_bb0110","author":"Office of National Statistics (ONS)"},{"issue":"7","key":"10.1016\/j.bcmd.2021.102567_bb0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1535370216640385","article-title":"Minireview: clinical severity in sickle cell disease: the challenges of definition and prognostication","volume":"241","author":"Quinn","year":"2016","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.bcmd.2021.102567_bb0120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.13348","article-title":"Guideline on the management of acute chest syndrome in sickle cell disease","volume":"169","author":"Howard","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102567_bb0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/ehm.11.61","article-title":"The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease","volume":"4","author":"Strouse","year":"2011","journal-title":"Expert. Rev. Hematol."},{"issue":"7","key":"10.1016\/j.bcmd.2021.102567_bb0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.bcmd.2021.102567_bb0135","series-title":"Hydroxyurea Therapy Does Not Impact Current Survival Estimates in the East London Sickle Cell Cohort Study. Poster Presented at: Annual Sickle Cell and Thalassaemia Conference (ASCAT)","author":"Telfer","year":"2019"},{"key":"10.1016\/j.bcmd.2021.102567_bb0140","first-page":"648","article-title":"Evaluation of newborn sickle cell screening programme in England: 2010\u20132016","volume":"103","author":"Streetly","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bcmd.2021.102567_bb0145","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00277-012-1465-7","article-title":"A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births","volume":"91","author":"Voskaridou","year":"2012","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.bcmd.2021.102567_bb0150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/003335491613100221","article-title":"Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008","volume":"131","author":"Paulukonis","year":"2016","journal-title":"Public Health Rep."},{"key":"10.1016\/j.bcmd.2021.102567_bb0155","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00277-020-04233-w","article-title":"Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries","volume":"99","author":"Desai","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2021.102567_bb0160","author":"National Haemoglobinopathy Registry"},{"key":"10.1016\/j.bcmd.2021.102567_bb0165","author":"NHS Digital"},{"issue":"1","key":"10.1016\/j.bcmd.2021.102567_bb0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/pubmed\/fdr054","article-title":"Systematic review of discharge coding accuracy","volume":"34","author":"Burns","year":"2012","journal-title":"J. Public Health"},{"issue":"5","key":"10.1016\/j.bcmd.2021.102567_bb0175","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood.V89.5.1787","article-title":"Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease","volume":"89","author":"Vichinsky","year":"1997","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102567_bb0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.bcmd.2021.102567_bb0185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/pubmed\/fds035","article-title":"Trends in hospital admissions for sickle cell disease in England, 2001\/02\u20132009\/10","volume":"34","author":"Aljuburi","year":"2012","journal-title":"J. Public Health"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:18Z","timestamp":1761050178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979621000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":37,"alternative-id":["S1079979621000334"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102567","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-morbidities and mortality in patients with sickle cell disease in England: A 10-year cohort analysis using hospital episodes statistics (HES) data","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102567"}}